p27 Y88 therapeutic peptide

p27 Y88 therapeutic peptide (also known as ALT or IpY) is a preclinical-stage therapeutic peptide developed by Concarlo Therapeutics (originally originated at SUNY Downstate Medical Center) for the treatment of drug-resistant cancers, particularly hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC). The peptide is designed to mimic the SH3 domain of breast tumor kinase (BRK/PTK6), allowing it to bind to the master cell cycle regulator p27 (CDKN1B). This binding blocks BRK-mediated phosphorylation of p27 at the tyrosine 88 (Y88) residue. Preventing Y88 phosphorylation maintains p27 in a stable, non-phosphorylated state, preventing its ubiquitin-mediated degradation. Consequently, stabilized p27 remains bound to and coordinates the simultaneous inhibition of cyclin-dependent kinases CDK2, CDK4, and CDK6, halting cell cycle progression and inducing tumor cell necroptosis. The peptide has been formulated in liposomes (as NP-ALT or IpY.20) to improve stability and cellular delivery.

Other names

ALTALT peptideBrk-SH3 peptideBrk-SH-3 peptideBrk-SH 3 peptideNP-ALTp27 Y88 therapeutic peptidep-27 Y88 therapeutic peptidep 27 Y88 therapeutic peptide